Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma

Kara M. Kelly, David Hodgson, Burton Appel, Lu Chen, Peter D. Cole, Terzah Horton, Frank G. Keller

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

In childhood Hodgkin lymphoma, estimated 5 years survival rates exceed 90%. Long-term survival continues to decline from delayed toxicities. Key findings from recent Children's Oncology Group trials include: (1) Radiotherapy selection may be based on early chemotherapy response assessed by both FDG-PET and CT imaging, (2) A new prognostic factor score stratifies patients into risk categories; and (3) novel retrieval regimens were identified. A phase I/II trial is investigating Brentuximab vedotin (Bv) with gemcitabine in relapsed patients. A phase 3 trial will modify conventional chemotherapy and radiotherapy approaches through the addition of Bv, while incorporating translational biology to identify molecular targets.

Original languageEnglish (US)
Pages (from-to)972-978
Number of pages7
JournalPediatric Blood and Cancer
Volume60
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

gemcitabine
Hodgkin Disease
Radiotherapy
Drug Therapy
Research
Survival Rate
Survival
cAC10-vcMMAE

Keywords

  • Biomarkers
  • Children
  • Clinical trials
  • Hodgkin lymphoma
  • Malignancies

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Kelly, K. M., Hodgson, D., Appel, B., Chen, L., Cole, P. D., Horton, T., & Keller, F. G. (2013). Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatric Blood and Cancer, 60(6), 972-978. https://doi.org/10.1002/pbc.24423

Children's Oncology Group's 2013 blueprint for research : Hodgkin lymphoma. / Kelly, Kara M.; Hodgson, David; Appel, Burton; Chen, Lu; Cole, Peter D.; Horton, Terzah; Keller, Frank G.

In: Pediatric Blood and Cancer, Vol. 60, No. 6, 06.2013, p. 972-978.

Research output: Contribution to journalArticle

Kelly, KM, Hodgson, D, Appel, B, Chen, L, Cole, PD, Horton, T & Keller, FG 2013, 'Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma', Pediatric Blood and Cancer, vol. 60, no. 6, pp. 972-978. https://doi.org/10.1002/pbc.24423
Kelly KM, Hodgson D, Appel B, Chen L, Cole PD, Horton T et al. Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatric Blood and Cancer. 2013 Jun;60(6):972-978. https://doi.org/10.1002/pbc.24423
Kelly, Kara M. ; Hodgson, David ; Appel, Burton ; Chen, Lu ; Cole, Peter D. ; Horton, Terzah ; Keller, Frank G. / Children's Oncology Group's 2013 blueprint for research : Hodgkin lymphoma. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 6. pp. 972-978.
@article{1eb11642f4414cba8bb6806afed35ef0,
title = "Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma",
abstract = "In childhood Hodgkin lymphoma, estimated 5 years survival rates exceed 90{\%}. Long-term survival continues to decline from delayed toxicities. Key findings from recent Children's Oncology Group trials include: (1) Radiotherapy selection may be based on early chemotherapy response assessed by both FDG-PET and CT imaging, (2) A new prognostic factor score stratifies patients into risk categories; and (3) novel retrieval regimens were identified. A phase I/II trial is investigating Brentuximab vedotin (Bv) with gemcitabine in relapsed patients. A phase 3 trial will modify conventional chemotherapy and radiotherapy approaches through the addition of Bv, while incorporating translational biology to identify molecular targets.",
keywords = "Biomarkers, Children, Clinical trials, Hodgkin lymphoma, Malignancies",
author = "Kelly, {Kara M.} and David Hodgson and Burton Appel and Lu Chen and Cole, {Peter D.} and Terzah Horton and Keller, {Frank G.}",
year = "2013",
month = "6",
doi = "10.1002/pbc.24423",
language = "English (US)",
volume = "60",
pages = "972--978",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Children's Oncology Group's 2013 blueprint for research

T2 - Hodgkin lymphoma

AU - Kelly, Kara M.

AU - Hodgson, David

AU - Appel, Burton

AU - Chen, Lu

AU - Cole, Peter D.

AU - Horton, Terzah

AU - Keller, Frank G.

PY - 2013/6

Y1 - 2013/6

N2 - In childhood Hodgkin lymphoma, estimated 5 years survival rates exceed 90%. Long-term survival continues to decline from delayed toxicities. Key findings from recent Children's Oncology Group trials include: (1) Radiotherapy selection may be based on early chemotherapy response assessed by both FDG-PET and CT imaging, (2) A new prognostic factor score stratifies patients into risk categories; and (3) novel retrieval regimens were identified. A phase I/II trial is investigating Brentuximab vedotin (Bv) with gemcitabine in relapsed patients. A phase 3 trial will modify conventional chemotherapy and radiotherapy approaches through the addition of Bv, while incorporating translational biology to identify molecular targets.

AB - In childhood Hodgkin lymphoma, estimated 5 years survival rates exceed 90%. Long-term survival continues to decline from delayed toxicities. Key findings from recent Children's Oncology Group trials include: (1) Radiotherapy selection may be based on early chemotherapy response assessed by both FDG-PET and CT imaging, (2) A new prognostic factor score stratifies patients into risk categories; and (3) novel retrieval regimens were identified. A phase I/II trial is investigating Brentuximab vedotin (Bv) with gemcitabine in relapsed patients. A phase 3 trial will modify conventional chemotherapy and radiotherapy approaches through the addition of Bv, while incorporating translational biology to identify molecular targets.

KW - Biomarkers

KW - Children

KW - Clinical trials

KW - Hodgkin lymphoma

KW - Malignancies

UR - http://www.scopus.com/inward/record.url?scp=84876452914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876452914&partnerID=8YFLogxK

U2 - 10.1002/pbc.24423

DO - 10.1002/pbc.24423

M3 - Article

C2 - 23255501

AN - SCOPUS:84876452914

VL - 60

SP - 972

EP - 978

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -